✦ LIBER ✦

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

✍ Scribed by Chapman, Kenneth R; Beeh, Kai-Michael; Beier, Jutta; Bateman, Eric D; D’Urzo, Anthony; Nutbrown, Robert; Henley, Michelle; Chen, Hungta; Overend, Tim; D’Andrea, Peter

Book ID: 121559485
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 225 KB
Volume: 14
Category: Article
ISSN: 1471-2466
DOI: 10.1186/1471-2466-14-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the long-acting m

Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD

✍ Eric Bateman; Gregory Feldman; Sally Kilbride; Jean Brooks; Rashmi Mehta; Stepha 📂 Article 📅 2012 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 546 KB

Safety and tolerability of NVA237, a onc

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

✍ C. Vogelmeier; C. Verkindre; D. Cheung; J.B. Galdiz; S.Z. Güçlü; S. Spangenthal; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 457 KB

Tu1059 A Phase 3, Randomized, Double-Bli

Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis

✍ Iwakiri, Katsuhiko; Umegaki, Eiji; Hiramatsu, Naoki; Sakurai, Yuuichi; Hori, Tet 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A randomized, multicenter, double-blind,

A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in adults with tinea cruris

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

80* A randomised, double-blind, placebo-

80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis

✍ J.S. Elborn; A. Sharma; Q. Deng; P. Koker 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A prospective, controlled, randomized, n

A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients

✍ Simeon Metallidis; Panagiotis Kollaras; Theodoros Giannakakis; Basilis Seitanidi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 149 KB